MedPath

Comparing TR Band to Statseal in Conjunction With TR Band

Not Applicable
Completed
Conditions
Anticoagulant-Induced Bleeding
Coronary Artery Disease
Cardiovascular Diseases
Arterial Occlusion
Atherosclerosis
Hematoma
Angina Pectoris
Registration Number
NCT03028025
Lead Sponsor
VA Long Beach Healthcare System
Brief Summary

The primary objectives of this study are to evaluate the performance of StatSeal Advanced used in conjunction with the TR Band (SSA) as compared to the TR Band without SSA (TRB) relative to: the incidence of peri-procedural radial artery occlusion (RAO) at discharge or 24 hours, whichever occurs first, and the Time to Hemostasis (TTH).

Detailed Description

This study is a physician initiated, prospective, observational, two arm, randomized study to be performed at up to four experienced 'Radial First' centers (UCSD, UCLA. Arkansas Heart Hospital and LBVA). A maximum of 180 patients having undergone successful radial catheterization will be enrolled in the study, 60 in each arm. 60 patients will be enrolled at the LBVA. Enrollment will continue at each site on discretion of the investigators until each center enrolls a minimum of 30 patients, or a maximum of 180 patients are enrolled. Clinicians will perform the catheterization in accordance with local standard practice, with a minimum of 5,000 units of unfractionated heparin for anticoagulation. At the start of the TRA procedure, prior to radial artery cannulation, a baseline Pleth-ox exam will be performed for all patients and recorded on the CRF. Ulnar compression will be applied to confirm that the radial artery is patent. Patients with a type D pattern exam will be excluded from the study. At the conclusion of a successful transradial procedure, the patient will be randomized to either SSA or TRB, each device applied per protocol \& IFU. It is hypothesized that if radial artery compression time can be shortened to 40 minutes or less, the following could result: improved catheterization lab efficiency, greater patient satisfaction and lower complication rates, including RAO, may be improved.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
184
Inclusion Criteria
  • Patient undergoing diagnostic angiography or PCI via the radial artery
  • Patients with a Barbeau test prior to the procedure showing pattern A,B,or
Exclusion Criteria
  • Use of a radial sheath larger than 6 Fr (a 7Fr-in-6 Glidesheath Slender ® is allowed).
  • Use of an anticoagulant other than unfractionated heparin or bivalirudin.
  • Any anticipated need for continued anticoagulation post-catheterization. Glycoprotein inhibitors are acceptable.
  • Any active treatment with oral anticoagulants continued during course of procedure.
  • Presence of arteriovenous dialysis fistula in the ipsilateral arm.
  • Any physical deformity or trauma / injury of either wrist that would prevent proper placement or function of the hemostasis band.
  • Raynaud's syndrome or known peripheral vascular disease of the forearm.
  • Mental incompetence or inability to follow the instructions to complete the study.
  • History or presence of Radial Artery Occlusion.
  • Barbeau test showing Pattern D.
  • Patients undergoing catheterization from the femoral or ulnar artery approach.
  • Cardiogenic shock or any clinical instability as assessed by the physician performing the procedure.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Time to Hemostasis Using the Hemostasis Management System (HMS)within 30 min of discharge or after 24 hours

Time to deflation for removal of the TR Band (or TR Band and Statseal) for each group was measured in minutes.

Secondary Outcome Measures
NameTimeMethod
Percent of Patients With Radial Artery Occlusion(RAO)within 30 min of discharge or after 24 hours

Radial artery occlusion was monitored for all participants using Barbeau's test and pulse oximetry.

Trial Locations

Locations (1)

Veteran Affairs Long Beach

🇺🇸

Long Beach, California, United States

Veteran Affairs Long Beach
🇺🇸Long Beach, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.